Treatment of Carcinoid Syndrome in Carcinoid Heart Disease with Right-Sided Valve Regurgitation
This protocol addresses carcinoid syndrome presenting in patients with carcinoid heart disease — characterised by right-sided heart valve regurgitation or stenosis, elevated urinary 5-HIAA, elevated NT-proBNP, and progression to right heart failure.
Clinical scenario: Carcinoid heart disease (CHD) is a rare and complex cardiac complication occurring in patients with advanced NETs and carcinoid syndrome, usually manifesting mainly as right-sided heart valve regurgitation or stenosis and eventually leading to right heart failure (RHF). Elevated u5-HIAA and elevated NT-proBNP are characteristic biochemical markers of this presentation.
Management approach
Management in this setting targets two simultaneous priorities: aggressive reduction of tumour-related hormonal secretion, and active treatment of right heart failure when present. Specific measures directed at symptomatic right heart failure are a core component of the approach — but they carry an important caution regarding how they are applied.
Clinical goal: improvement of right heart failure symptoms.
The complete regimen, decision pathway, and full clinical sequencing are in the structured protocol below.
References
DOI: 10.1111/jne.13146
- Carcinoid heart disease (CHD) is a rare and complex cardiac complication occurring in patients with advanced NETs and CS, usually manifesting mainly as right-sided heart valves regurgitation/stenosis (see Section A. d.) and eventually leading to right heart failure (RHF).
- The two main goals of management are aggressive reduction of hormonal secretion by the tumour and management of CHD and RHF, when present.
- In patients with symptomatic RHF, standard treatments, including loop/thiazide diuretics, aldosterone antagonist therapy and cautious fluid and salt restriction, can improve patient's symptoms but must be used judiciously to avoid a paradoxical worsening of symptoms because of a reduction in cardiac output.
View source ↗